Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Continues Tough Approach On Cancer Drugs, Rejects Tarceva, Javlor and Yondelis

This article was originally published in The Pink Sheet Daily

Executive Summary

The British drug costs regulator turns down Roche's Tarceva, Pierre Fabre's Javlor and PharmaMar's Yondelis for use in the NHS in certain indications.
Advertisement

Related Content

Javlor Falls Short Again At NICE; Even Sole Treatment In Class Faces Cost Hurdle
With Yervoy Approved in Europe, Bristol Activates Reimbursement Talks
With Yervoy Approved in Europe, Bristol Activates Reimbursement Talks
NICE, In Final Decision, Rejects Roche's Tarceva For Lung Cancer Maintenance
NICE, In Final Decision, Rejects Roche's Tarceva For Lung Cancer Maintenance
NICE Rejects Leukemia Drugs On Eve Of Conference That Likely Will Debate Cancer Policies, NICE's Future
NICE Rejects Leukemia Drugs On Eve Of Conference That Likely Will Debate Cancer Policies, NICE's Future
Regional Disparities Threaten Effectiveness Of U.K. Cancer Drugs Fund
Regional Disparities Threaten Effectiveness Of U.K. Cancer Drugs Fund
NICE Rejects Javlor, But Could Products For Unmet Clinical Needs Be Rethought?

Topics

Advertisement
UsernamePublicRestriction

Register

PS071937

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel